
Shuji Ozaki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7089032/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 191-203.	2.5	3
2	Multiple myeloma treatment $\hat{a} \in \hat{~}$ should be continued or not?. British Journal of Haematology, 2022, , .	2.5	0
3	Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma. Cancers, 2020, 12, 12.	3.7	25
4	Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. Annals of Hematology, 2019, 98, 1703-1711.	1.8	11
5	Patients assigned to VGPR, PR, and SD in the IMWG response category are composed of heterogeneous population when assessed by the heavy/light chain assay. Hematological Oncology, 2019, 37, 316-318.	1.7	1
6	JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM). International Journal of Hematology, 2019, 109, 509-538.	1.6	27
7	Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902). Annals of Hematology, 2016, 95, 921-929.	1.8	3
8	Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells. BioMed Research International, 2014, 2014, 1-7.	1.9	12
9	Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors. PLoS ONE, 2013, 8, e83905.	2.5	16
10	Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma. International Journal of Hematology, 2011, 93, 257-259.	1.6	4
11	A defucosylated anti D317 antibody exhibited enhanced antibodyâ€dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients. Cancer Science, 2010, 101, 2227-2233.	3.9	21
12	Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma. International Journal of Hematology, 2009, 89, 223-226.	1.6	9
13	HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunology, Immunotherapy, 2009, 58, 967-976.	4.2	57
14	Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells. Lung Cancer, 2009, 63, 23-31.	2.0	17
15	Interferonâ€Î± enhances CD317 expression and the antitumor activity of anti D317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Science, 2008, 99, 2461-2466.	3.9	41
16	Therapy with Bortezomib plus Dexamethasone Induces Osteoblast Activation in Responsive Patients with Multiple Myeloma. International Journal of Hematology, 2007, 86, 180-185.	1.6	50
17	Multi-Drug Resistant Leukemic Cells Highly Express HLA Class I Molecules and Single-Chain Fv Diabody Specific to HLA-A Overcomes Drug Resistance in These Cells Blood, 2007, 110, 2376-2376.	1.4	0
18	Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL Blood, 2007, 110, 244-244.	1.4	0

Shuji Ozaki

#	Article	IF	CITATIONS
19	The Serine/Threonine Kinase Pim-2 Is a Novel Anti-Apoptotic Mediator in Myeloma Cells Blood, 2007, 110, 243-243.	1.4	1
20	Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: Correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24. Leukemia Research, 2006, 30, 949-956.	0.8	13
21	SB431542, a TGF-Beta Receptor Kinase Inhibitor, Restores Bone Formation Which Ameliorates Myeloma-Induced Microenvironment Blood, 2006, 108, 3479-3479.	1.4	1
22	Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Oncology Reports, 2006, 15, 361-7.	2.6	30
23	Induction of HM1.24 peptide–specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. Blood, 2005, 106, 3538-3545.	1.4	39
24	Angiogenesis and Osteoclastogenesis Are Mutually Stimulated in Myeloma: A Role for VEGF and Osteopontin Blood, 2005, 106, 2500-2500.	1.4	0
25	Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That Is Enhanced by Cytokine Stimulation of Effector Cells. Blood, 1999, 93, 3922-3930.	1.4	56
26	The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity. Molecular Immunology, 1999, 36, 387-395.	2.2	37
27	Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma Cells. Biochemical and Biophysical Research Communications, 1999, 258, 583-591.	2.1	189
28	Biclonal Lymphoplasmacytic Immunocytoma Associated with Crohn's Disease Internal Medicine, 1999, 38, 500-503.	0.7	2
29	Radioimmunodetection of human myeloma xenografts with a monoclonal antibody directed against a plasma cell specific antigen, HM1.24. Cancer, 1998, 82, 2184-2190.	4.1	9
30	Radioimmunodetection of human myeloma xenografts with a monoclonal antibody directed against a plasma cell specific antigen, HM1.24. , 1998, 82, 2184.		1
31	Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24. Blood, 1997, 90, 3179-3186.	1.4	75
32	Thrombopoietinâ€responsive essential thrombocythaemia with myelofibrosis. British Journal of Haematology, 1997, 97, 449-452.	2.5	8
33	Variable-region subgroup distribution among λ-type immunoglobulins in normal human serum. Journal of Clinical Laboratory Analysis, 1994, 8, 4-9.	2.1	16
34	Enzyme-linked immunosorbent assay for variable region .LAMBDA. VI subgroup of light chain in serum: method and results in normal subjects and patients with hyper- and hypogammaglobulinemia Japanese Journal of Clinical Immunology, 1994, 17, 172-181.	0.0	0